CD274 and neoplasm: Therapeutic interventions targeting TANs have diversified: (1)Phenotype conversion: Galunisertib (a TGF-β receptor inhibitor) combined with atezolizumab (anti-PD-L1) reduced tumour volume by 62% (p < 0.001) by reversing N2 polarisation towards an N1 phenotype (142).